BRPI0919295A2 - 1h-benzimidazol-5-carboxamidas como agentes anti-inflamatórios. - Google Patents

1h-benzimidazol-5-carboxamidas como agentes anti-inflamatórios.

Info

Publication number: BRPI0919295A2
Authority: BR; Brazil
Prior art keywords: carboxamides; benzimidazole; inflammatory agents; inflammatory; agents
Prior art date: 2008-09-25

Application number

BRPI0919295A

Other languages

English (en)

Inventor

Dirk Stenkamp

Henning Priepke

Henri Doods

Juergen Mack

Kirsten Arndt

Klaus Klinder

Norbert Hauel

Raimund Kuelzer

Roland Pfau

Original Assignee

Boehringer Ingelheim Int

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-09-25

Filing date

2009-09-25

Publication date

2015-12-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40344110&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0919295(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-09-25 Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int

2015-12-15 Publication of BRPI0919295A2 publication Critical patent/BRPI0919295A2/pt

Links

FNLQDVXHDNFXIY-UHFFFAOYSA-N 3h-benzimidazole-5-carboxamide Chemical class NC(=O)C1=CC=C2NC=NC2=C1 FNLQDVXHDNFXIY-UHFFFAOYSA-N 0.000 title 1
229940121363 anti-inflammatory agent Drugs 0.000 title 1
239000002260 anti-inflammatory agent Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Physical Education & Sports Medicine (AREA)
Immunology (AREA)
Neurology (AREA)
Pulmonology (AREA)
Biomedical Technology (AREA)
Rheumatology (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Orthopedic Medicine & Surgery (AREA)
Oncology (AREA)
Endocrinology (AREA)
Communicable Diseases (AREA)
Dermatology (AREA)
Pain & Pain Management (AREA)
Reproductive Health (AREA)
Urology & Nephrology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Hematology (AREA)
Vascular Medicine (AREA)
Emergency Medicine (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Ophthalmology & Optometry (AREA)
Obesity (AREA)

BRPI0919295A 2008-09-25 2009-09-25 1h-benzimidazol-5-carboxamidas como agentes anti-inflamatórios. BRPI0919295A2 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US9998708P	2008-09-25	2008-09-25
EP08165120		2008-09-25
PCT/EP2009/062421 WO2010034796A1 (en)	2008-09-25	2009-09-25	1h-benz imidazole-5-carboxamides as anti-inflammatory agents

Publications (1)

Publication Number	Publication Date
BRPI0919295A2 true BRPI0919295A2 (pt)	2015-12-15

Family

ID=40344110

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
BRPI0919295A BRPI0919295A2 (pt)	2008-09-25	2009-09-25	1h-benzimidazol-5-carboxamidas como agentes anti-inflamatórios.
BRPI0919738A BRPI0919738A2 (pt)	2008-09-25	2009-09-25	3h-imidazo[4,5-c] piridino-6-carboxamidas como agentes anti-inflamatórios
BRPI0919292A BRPI0919292A2 (pt)	2008-09-25	2009-09-25	3h-imidazo[4,5-b] piridina-6-carboxamidas como agentes anti-inflamatórios

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
BRPI0919738A BRPI0919738A2 (pt)	2008-09-25	2009-09-25	3h-imidazo[4,5-c] piridino-6-carboxamidas como agentes anti-inflamatórios
BRPI0919292A BRPI0919292A2 (pt)	2008-09-25	2009-09-25	3h-imidazo[4,5-b] piridina-6-carboxamidas como agentes anti-inflamatórios

Country Status (17)

Country	Link
US (4)	US8703796B2 (pt)
EP (4)	EP2361252A1 (pt)
JP (4)	JP5591807B2 (pt)
KR (4)	KR20110060910A (pt)
CN (4)	CN102164911A (pt)
AR (4)	AR073686A1 (pt)
AU (4)	AU2009295813A1 (pt)
BR (3)	BRPI0919295A2 (pt)
CA (4)	CA2738083A1 (pt)
IL (4)	IL211137A0 (pt)
MX (4)	MX2011002948A (pt)
NZ (4)	NZ591846A (pt)
RU (4)	RU2011116133A (pt)
TW (4)	TW201018669A (pt)
UY (1)	UY32138A (pt)
WO (4)	WO2010034797A1 (pt)
ZA (2)	ZA201101041B (pt)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20100250458A1 (en) *	2009-03-30	2010-09-30	Mspot, Inc.	Content based social networking system and method
UY32138A (es)	2008-09-25	2010-04-30	Boehringer Ingelheim Int	Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables
CN102361857B (zh) *	2008-09-26	2015-09-16	默沙东公司	可用作抗糖尿病剂的环状苯并咪唑衍生物
UY32470A (es)	2009-03-05	2010-10-29	Boehringer Ingelheim Int	Derivados de 2-{2-cloro-5-[(sustituido) metil]fenilamino} -1-metil]fenilamino}-1-metilbencimidazol-5-carboxamidas-n-(sustituidas) y sus sales fisiológicamente aceptables, composiciones conteniéndolos y aplicaciones
EP3078377A3 (en)	2009-05-12	2017-04-05	Romark Laboratories, L.C.	Nitazoxanide and tizoxanide as anti-viral agents
MX341877B (es)	2009-06-26	2016-09-06	Romark Laboratories L C *	Compuestos y métodos para tratar influenza.
WO2011099832A2 (en) *	2010-02-12	2011-08-18	Crystalgenomics, Inc.	Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same
US8586604B2 (en)	2010-08-20	2013-11-19	Boehringer Ingelheim International Gmbh	Inhibitors of the microsomal prostaglandin E2 synthase-1
US8759537B2 (en) *	2010-08-20	2014-06-24	Boehringer Ingelheim International Gmbh	3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents
TW201305178A (zh)	2010-10-29	2013-02-01	Glenmark Pharmaceuticals Sa	作為ｍＰＧＥＳ－１抑制物的三環化合物
US8466186B2 (en)	2010-12-10	2013-06-18	Boehringer Ingelheim International Gmbh	Compounds
UY33779A (es) *	2010-12-10	2012-07-31	Boehringer Ingelheim Int	?2-(fenilamino)-1H-bencimidazol-5-carboxamidas novedosas?
US8486968B2 (en) *	2010-12-10	2013-07-16	Boehringer Ingelheim International Gmbh	Compounds
AR084174A1 (es)	2010-12-21	2013-04-24	Lilly Co Eli	Compuestos de imidazol-2-benzamida utiles para el tratamiento de osteoartritis y una composicion farmaceutica
WO2012102937A2 (en) *	2011-01-25	2012-08-02	Irm Llc	Compounds that expand hematopoietic stem cells
MX348131B (es) *	2011-02-25	2017-05-26	Merck Sharp & Dohme	Novedosos derivados de azabencimidazol ciclico utiles como agentes antidiabeticos.
EP2495244A1 (en)	2011-03-02	2012-09-05	NovaSaid AB	Piperidinyl benzoimidazole derivatives as mPGEs-1 inhibitors
JP6162694B2 (ja)	2011-07-18	2017-07-12	メルクパテントゲゼルシャフトミットベシュレンクテルハフツングＭｅｒｃｋＰａｔｅｎｔＧｅｓｅｌｌｓｃｈａｆｔｍｉｔｂｅｓｃｈｒａｅｎｋｔｅｒＨａｆｔｕｎｇ	ベンズアミド類
WO2013038308A1 (en)	2011-09-15	2013-03-21	Glenmark Pharmaceuticals S.A.	SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS AS mPGES-1 INHIBITORS
WO2013072825A1 (en)	2011-11-16	2013-05-23	Glenmark Pharmaceuticals S.A.	Phtalazinone derivatives as mpegs -1 inhibitors
US9006257B2 (en)	2012-02-09	2015-04-14	Glenmark Pharmaceuticals S.A.	Bicyclic compounds as mPGES-1 inhibitors
WO2013153535A1 (en)	2012-04-13	2013-10-17	Glenmark Pharmaceuticals S.A.	TRICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS
CN103450329B (zh) *	2012-05-29	2015-05-27	首都医科大学	3h-咪唑并吡啶-6-甲酰氨基酸苄酯、其合成、抗肿瘤活性和应用
CA2874303C (en)	2012-06-11	2020-10-13	Ucb Biopharma Sprl	Tnf -alpha modulating benz imidazoles
TWI568722B (zh)	2012-06-15	2017-02-01	葛蘭馬克製藥公司	作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物
CN103922999B (zh) *	2013-01-16	2016-05-04	上海医药工业研究院	一种达比加群酯中间体的制备方法及中间体化合物
US20140221335A1 (en) *	2013-02-06	2014-08-07	Boehringer Ingelheim International Gmbh	Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
CN104030977B (zh) *	2013-03-07	2016-05-04	上海医药工业研究院	一种达比加群酯中间体的制备方法
WO2014167444A1 (en)	2013-04-08	2014-10-16	Glenmark Pharmaceuticals S.A.	SUBSTITUTED BICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS
AR096684A1 (es) *	2013-06-25	2016-01-27	Ptc Therapeutics Inc	Compuestos para tratar atrofia muscular espinal
CN103435554A (zh) *	2013-09-06	2013-12-11	中国药科大学	2-苯氨基苯并咪唑类化合物及其用途
WO2015059618A1 (en)	2013-10-22	2015-04-30	Glenmark Pharmaceuticals S.A.	SUBSTITUTED PYRIMIDINE COMPOUNDS AS mPGES-1 INHIBITORS
CA2939021C (en)	2014-02-11	2022-07-12	Bayer Pharma Aktiengesellschaft	Benzimidazol-2-amines as midh1 inhibitors
BR112016018604A2 (pt)	2014-02-11	2017-08-08	Bayer Pharma AG	Benzimidazol-2-aminas como inibidores de midh1
WO2015166398A1 (en) *	2014-04-30	2015-11-05	Aurigene Discovery Technologies Limited	3h-imidazo[4,5-b]pyridine derivatives as dihydroorotate dehydrogenase inhibitors
CN105198959B (zh) *	2014-06-13	2018-09-07	首都医科大学	咪唑并吡啶-6-甲酰-Met-Glu(OBzl)2,其合成,活性和应用
CN105198960B (zh) *	2014-06-13	2018-10-19	首都医科大学	咪唑并吡啶-6-甲酰-Met-AA-OBzl,其合成,活性和应用
CN105294829B (zh) *	2014-06-13	2018-07-27	首都医科大学	咪唑并吡啶-6-甲酰-氨基酸苄酯，其合成，活性及应用
CN105254709A (zh) *	2014-07-10	2016-01-20	首都医科大学	咪唑并吡啶-6-甲酰-Met-AA-OBzl,其合成,活性和应用
CN105315335A (zh) *	2014-07-10	2016-02-10	首都医科大学	咪唑并吡啶-6-甲酰-Met-Gln-OBzl,其合成,活性和应用
CN105315325A (zh) *	2014-07-10	2016-02-10	首都医科大学	咪唑并吡啶-6-甲酰-Met-Arg(NO2)-OBzl,其合成,活性和应用
HUE044602T2 (hu)	2014-08-01	2019-11-28	Glenmark Pharmaceuticals Sa	Nanorészecskés készítmény, amely egy MPGES-1 inhibitorot tartalmaz
JP6645695B2 (ja) *	2014-10-14	2020-02-14	中尾　洋一	イミダゾピリジンアミン化合物、その製造方法及び用途
EP3209660B1 (en)	2014-10-23	2020-06-17	Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts	1-cyclohexyl-2-phenylaminobenzimidazoles as midh1 inhibitors for the treatment of tumors
WO2016062677A1 (en) *	2014-10-23	2016-04-28	Bayer Pharma Aktiengesellschaft	Benzimidazol-2-amines as midh1 inhibitors
CN106146615B (zh) *	2015-03-23	2021-08-24	首都医科大学	咪唑并吡啶-6-甲酰-氨基酸苄酯，其合成，活性和应用
CA2986199C (en)	2015-05-21	2023-07-18	Glaxosmithkline Intellectual Property Development Limited	Benzoimidazole derivatives as pad4 inhibitors
EP3303302B1 (en)	2015-06-08	2019-03-20	Bayer Pharma Aktiengesellschaft	N-menthylbenzimidazoles as midh1 inhibitors
CN107698660B (zh) *	2015-06-23	2021-06-08	首都医科大学	咪唑并吡啶-6-甲酰-Lys(Lys)-寡肽,其合成,活性和应用
US10414734B2 (en)	2015-07-16	2019-09-17	Bayer Pharma Aktiengesellschaft	5-hydroxyalkylbenzimidazoles as mIDH1 inhibitors
US10894784B2 (en)	2015-12-18	2021-01-19	Bayer Pharma Aktiengesellschaft	Heteroarylbenzimidazole compounds
WO2017207534A1 (en)	2016-06-03	2017-12-07	Bayer Pharma Aktiengesellschaft	Substituted heteroarylbenzimidazole compounds
CA3079483A1 (en)	2017-11-22	2019-05-31	Khondrion Ip B.V.	Compounds as mpges-1 inhibitors
CN110294751B (zh) *	2018-03-21	2020-11-20	湖南化工研究院有限公司	具生物活性的咪唑[4,5-b]并吡啶类化合物及其制备方法和应用
EP3876939A4 (en)	2018-11-07	2022-08-10	Dana-Farber Cancer Institute, Inc.	Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
EP3876930A4 (en)	2018-11-07	2022-07-20	Dana-Farber Cancer Institute, Inc.	BENZIMIDAZOLE DERIVATIVES AND AZA-BENZIMIDAZOLE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF
WO2020097400A1 (en)	2018-11-07	2020-05-14	Dana-Farber Cancer Institute, Inc.	Imidazopyridine derivatives and aza-imidazopyridine derivatives as janus kinase 2 inhibitors and uses thereof
AU2020301161B2 (en)	2019-06-25	2023-10-26	Gilead Sciences, Inc.	FLT3L-Fc fusion proteins and methods of use
GB201910608D0 (en) *	2019-07-24	2019-09-04	Enterprise Therapeutics Ltd	Compounds
KR102902719B1 (ko)	2019-10-18	2025-12-24	포티 세븐, 엘엘씨	골수이형성 증후군 및 급성 골수성 백혈병을 치료하기 위한 조합 치료
CA3153636A1 (en)	2019-10-31	2021-05-06	Forty Seven, Inc.	Anti-cd47 and anti-cd20 based treatment of blood cancer
TWI778443B (zh)	2019-11-12	2022-09-21	美商基利科學股份有限公司	Mcl1抑制劑
CN115151540A (zh) *	2019-12-02	2022-10-04	风暴治疗有限公司	作为mettl3抑制剂的多杂环化合物
EP4445902A3 (en)	2019-12-24	2024-12-18	Carna Biosciences, Inc.	Diacylglycerol kinase modulating compounds
WO2021131549A1 (ja) *	2019-12-26	2021-07-01	セイカ株式会社	ジアミノビフェニル化合物の製造方法
KR20220130179A (ko)	2020-01-20	2022-09-26	젠자임 코포레이션	재발성 다발성 경화증(rms)에 대한 치료용 티로신 키나제 저해제
CN117964757A (zh)	2020-02-14	2024-05-03	吉利德科学公司	与ccr8结合的抗体和融合蛋白及其用途
US12110294B2 (en)	2020-05-01	2024-10-08	Gilead Sciences, Inc.	CD73 compounds
BR112022022409A2 (pt)	2020-05-06	2023-02-07	Ajax Therapeutics Inc	6-heteroarilóxi benzimidazóis e azabenzimidazóis como inibidores de jak2
CN114249694B (zh) *	2020-09-22	2025-06-17	浙江四维医药科技有限公司	一种特格拉赞中间体的制备方法
CN118434732A (zh)	2020-12-10	2024-08-02	建新公司	Tolebrutinib的晶型及其制备方法和用途
WO2022140527A1 (en)	2020-12-23	2022-06-30	Ajax Therapeutics, Inc.	6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
WO2022140511A1 (en)	2020-12-23	2022-06-30	Genzyme Corporation	4-amino-3-(4-phenoxyphenyl)-1,3- dihydro-2h-imidazo[4,5-c]pyridin-2-one derivatives and salts thereof
TW202302145A (zh)	2021-04-14	2023-01-16	美商基利科學股份有限公司	ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
TW202313094A (zh)	2021-05-18	2023-04-01	美商基利科學股份有限公司	使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法
WO2022271659A1 (en)	2021-06-23	2022-12-29	Gilead Sciences, Inc.	Diacylglyercol kinase modulating compounds
EP4359415A1 (en)	2021-06-23	2024-05-01	Gilead Sciences, Inc.	Diacylglyercol kinase modulating compounds
WO2022271650A1 (en)	2021-06-23	2022-12-29	Gilead Sciences, Inc.	Diacylglyercol kinase modulating compounds
US11932634B2 (en)	2021-06-23	2024-03-19	Gilead Sciences, Inc.	Diacylglycerol kinase modulating compounds
AU2022376954B2 (en)	2021-10-29	2026-04-23	Gilead Sciences, Inc.	Cd73 compounds
CA3234638A1 (en)	2021-11-09	2023-05-19	Ajax Therapeutics, Inc.	6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
WO2023086320A1 (en)	2021-11-09	2023-05-19	Ajax Therapeutics, Inc.	Forms and compositions of inhibitors of jak2
AU2022419982B2 (en)	2021-12-22	2026-04-16	Gilead Sciences, Inc.	Ikaros zinc finger family degraders and uses thereof
CA3237577A1 (en)	2021-12-22	2023-06-29	Gilead Sciences, Inc.	Ikaros zinc finger family degraders and uses thereof
TW202340168A (zh)	2022-01-28	2023-10-16	美商基利科學股份有限公司	Ｐａｒｐ７抑制劑
EP4493554A1 (en)	2022-03-17	2025-01-22	Gilead Sciences, Inc.	Ikaros zinc finger family degraders and uses thereof
WO2023183817A1 (en)	2022-03-24	2023-09-28	Gilead Sciences, Inc.	Combination therapy for treating trop-2 expressing cancers
TWI876305B (zh)	2022-04-05	2025-03-11	美商基利科學股份有限公司	用於治療結腸直腸癌之組合療法
CR20240451A (es)	2022-04-21	2024-12-04	Gilead Sciences Inc	Compuestos de modulación de kras g12d
PE20250758A1 (es)	2022-07-01	2025-03-13	Gilead Sciences Inc	Compuestos de cd73
US20260042743A1 (en) *	2022-08-01	2026-02-12	Council Of Scientific And Industrial Research	Substituted benzimidazoles for treating viral diseases
WO2024064668A1 (en)	2022-09-21	2024-03-28	Gilead Sciences, Inc.	FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
CN120225509A (zh)	2022-12-22	2025-06-27	吉利德科学公司	Prmt5抑制剂及其用途
CN116332779B (zh) *	2023-03-13	2025-06-10	苏州敬业医药化工有限公司	一种3,4-二氨基苯甲酸甲酯的制备方法
JPWO2024190888A1 (pt) *	2023-03-16	2024-09-19
AU2024252725A1 (en)	2023-04-11	2025-11-06	Gilead Sciences, Inc.	Kras modulating compounds
PE20260121A1 (es)	2023-04-21	2026-01-16	Gilead Sciences Inc	Inhibidores de prmt5 y usos de los mismos
AU2024306338A1 (en)	2023-06-30	2026-01-08	Gilead Sciences, Inc.	Kras modulating compounds
WO2025024811A1 (en)	2023-07-26	2025-01-30	Gilead Sciences, Inc.	Parp7 inhibitors
KR20260046403A (ko)	2023-07-26	2026-04-07	길리애드 사이언시즈, 인코포레이티드	Parp7 저해제
US20250101042A1 (en)	2023-09-08	2025-03-27	Gilead Sciences, Inc.	Kras g12d modulating compounds
AU2024337913A1 (en)	2023-09-08	2026-03-26	Gilead Sciences, Inc.	Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
US20250154172A1 (en)	2023-11-03	2025-05-15	Gilead Sciences, Inc.	Prmt5 inhibitors and uses thereof
WO2025137640A1 (en)	2023-12-22	2025-06-26	Gilead Sciences, Inc.	Azaspiro wrn inhibitors
WO2025245003A1 (en)	2024-05-21	2025-11-27	Gilead Sciences, Inc.	Prmt5 inhibitors and uses thereof
WO2026039365A1 (en)	2024-08-12	2026-02-19	Gilead Sciences, Inc.	Kras modulating compounds
WO2026089992A1 (en)	2024-10-21	2026-04-30	Gilead Sciences, Inc.	Prmt5 inhibitors and uses thereof

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3006671A1 (de)	1980-02-22	1981-08-27	Dr. Karl Thomae Gmbh, 7950 Biberach	Neue benzoxazole, deren herstellung und deren verwendung als arzneumittel
FI91859C (fi)	1987-06-17	1994-08-25	Eisai Co Ltd	Analogiamenetelmä antiallergisena aineena aktiivisen bentsotiatsolijohdannaisen valmistamiseksi
JPH06759B2 (ja)	1989-09-22	1994-01-05	ファイザー製薬株式会社	新規なベンゾイミダゾール化合物
SK2612001A3 (en)	1998-08-26	2001-11-06	Aventis Pharma Ltd	Aza-bicycles which modulate the inhibition of cell adhesion
WO2000049005A1 (en)	1999-02-16	2000-08-24	Aventis Pharma Limited	Bicyclic compounds and their use as integrin receptor ligands
EE200100528A (et) *	1999-04-12	2003-02-17	Aventis Pharma Limited	Asendatud bitsükliline heteroarüülühend, seda sisaldav farmatseutiline kompositsioon ning nende raviotstarbeline kasutamine
ATE421958T1 (de)	1999-05-05	2009-02-15	Aventis Pharma Ltd	Substituierte bizyclische verbindungen
US6340681B1 (en)	1999-07-16	2002-01-22	Pfizer Inc	2-benzimidazolylamine compounds as ORL-1-receptor agonists
ATE277044T1 (de)	1999-10-06	2004-10-15	Boehringer Ingelheim Pharma	Heterocyclische verbindungen verwendbar als tyrosinkinase inhibitoren
FR2833948B1 (fr) *	2001-12-21	2004-02-06	Sod Conseils Rech Applic	Nouveaux derives de benzimidazole et leur utilisation en tant que medicament
US7338959B2 (en)	2002-03-01	2008-03-04	Smithkline Beecham Corporation	Diamino-pyrimidines and their use as angiogenesis inhibitors
ATE447404T1 (de)	2002-03-29	2009-11-15	Novartis Vaccines & Diagnostic	Substituierte benzazole und ihre verwendung als raf-kinase-hemmer
US7037902B2 (en)	2002-07-03	2006-05-02	Receptron, Inc.	Affinity small molecules for the EPO receptor
CA2502356A1 (en)	2002-10-15	2004-04-29	Synta Pharmaceuticals Corp.	Aromatic bicyclic heterocyles to modulate 1l - 12 production
AU2004212490B2 (en)	2003-02-10	2008-05-15	Amgen Inc.	Vanilloid receptor ligands and their use in treatments
FR2851563B1 (fr)	2003-02-26	2005-04-22	Sod Conseils Rech Applic	Nouveaux derives de benzimidazole et d'imidazo-pyridine et leur utilisation en tant que medicament
US7531553B2 (en)	2003-03-21	2009-05-12	Amgen Inc.	Heterocyclic compounds and methods of use
FR2852957B1 (fr)	2003-03-31	2005-06-10	Sod Conseils Rech Applic	Nouveaux derives d'imidazo-pyridine et leur utilisation en tant que medicament
US7329682B2 (en)	2003-04-03	2008-02-12	Ewha University-Industry Collaboration Foundation	Method for inhibiting 5-lipoxygenase using a benzoxazole derivative
CA2543707A1 (en)	2003-10-31	2005-05-19	Takeda Pharmaceutical Company Limited	Nitrogen-containing fused heterocyclic compounds
US7470712B2 (en)	2004-01-21	2008-12-30	Bristol-Myers Squibb Company	Amino-benzazoles as P2Y1 receptor inhibitors
GB0401334D0 (en) *	2004-01-21	2004-02-25	Novartis Ag	Organic compounds
US20080188473A1 (en)	2004-06-18	2008-08-07	Kristofer Olofsson	Indoles Useful in the Treatment of Inflammation
US7723340B2 (en) *	2005-01-13	2010-05-25	Signal Pharmaceuticals, Llc	Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
US7521446B2 (en)	2005-01-13	2009-04-21	Signal Pharmaceuticals, Llc	Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
ATE501119T1 (de) *	2005-01-19	2011-03-15	Biolipox Ab	Entzündungshemmende indol-derivate
JP2008531537A (ja)	2005-02-25	2008-08-14	クドスファーマシューティカルズリミテッド	化合物
MX2007011234A (es)	2005-03-14	2007-11-12	Transtech Pharma Inc	Derivados de benzazol, composiciones y metodos de uso en la forma de inhibidores de b-secretasa.
US20070173488A1 (en)	2005-11-16	2007-07-26	Sgx Pharmaceuticals, Inc.	Pyrazolothiazole Protein Kinase Modulators
AU2007215247B2 (en) *	2006-02-10	2012-12-13	Transtech Pharma, Llc	Benzazole derivatives, compositions, and methods of use as Aurora kinase inhibitors
US20070287344A1 (en) *	2006-06-12	2007-12-13	Hiroshi Ohara	Fabric Construction Specifically For Damper
WO2008009924A2 (en)	2006-07-18	2008-01-24	Biolipox Ab	Indoles useful in the treatment of inflammation
WO2008035956A1 (en)	2006-09-22	2008-03-27	Ewha University - Industry Collaboration Foundation	New benzoxazole derivative, process for the preparation thereof and pharmaceutical composition comprising the same
JP2010513253A (ja)	2006-12-14	2010-04-30	ベーリンガーインゲルハイムインテルナショナールゲーエムベーハー	炎症の治療に有用なベンゾオキサゾール類
WO2008129276A1 (en)	2007-04-19	2008-10-30	Boehringer Ingelheim International Gmbh	Disulfonamides useful in the treatment of inflammation
UY32138A (es)	2008-09-25	2010-04-30	Boehringer Ingelheim Int	Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables
UY32470A (es)	2009-03-05	2010-10-29	Boehringer Ingelheim Int	Derivados de 2-{2-cloro-5-[(sustituido) metil]fenilamino} -1-metil]fenilamino}-1-metilbencimidazol-5-carboxamidas-n-(sustituidas) y sus sales fisiológicamente aceptables, composiciones conteniéndolos y aplicaciones
US8586604B2 (en)	2010-08-20	2013-11-19	Boehringer Ingelheim International Gmbh	Inhibitors of the microsomal prostaglandin E2 synthase-1
US8759537B2 (en)	2010-08-20	2014-06-24	Boehringer Ingelheim International Gmbh	3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents
US8466186B2 (en)	2010-12-10	2013-06-18	Boehringer Ingelheim International Gmbh	Compounds
US8486968B2 (en) *	2010-12-10	2013-07-16	Boehringer Ingelheim International Gmbh	Compounds
UY33779A (es)	2010-12-10	2012-07-31	Boehringer Ingelheim Int	?2-(fenilamino)-1H-bencimidazol-5-carboxamidas novedosas?

2009
- 2009-09-24 UY UY0001032138A patent/UY32138A/es not_active Application Discontinuation
- 2009-09-25 EP EP09783405A patent/EP2361252A1/en not_active Withdrawn
- 2009-09-25 TW TW098132551A patent/TW201018669A/zh unknown
- 2009-09-25 AU AU2009295813A patent/AU2009295813A1/en not_active Abandoned
- 2009-09-25 CA CA2738083A patent/CA2738083A1/en not_active Abandoned
- 2009-09-25 NZ NZ591846A patent/NZ591846A/xx not_active IP Right Cessation
- 2009-09-25 EP EP09783403A patent/EP2334664A1/en not_active Withdrawn
- 2009-09-25 RU RU2011116133/04A patent/RU2011116133A/ru not_active Application Discontinuation
- 2009-09-25 EP EP09783406.3A patent/EP2350073B1/en not_active Not-in-force
- 2009-09-25 AR ARP090103705A patent/AR073686A1/es unknown
- 2009-09-25 RU RU2011116129/04A patent/RU2011116129A/ru not_active Application Discontinuation
- 2009-09-25 CN CN2009801376052A patent/CN102164911A/zh active Pending
- 2009-09-25 AU AU2009295815A patent/AU2009295815A1/en not_active Abandoned
- 2009-09-25 CA CA2737552A patent/CA2737552A1/en not_active Abandoned
- 2009-09-25 BR BRPI0919295A patent/BRPI0919295A2/pt not_active IP Right Cessation
- 2009-09-25 NZ NZ591843A patent/NZ591843A/xx not_active IP Right Cessation
- 2009-09-25 NZ NZ591847A patent/NZ591847A/xx not_active IP Right Cessation
- 2009-09-25 MX MX2011002948A patent/MX2011002948A/es active IP Right Grant
- 2009-09-25 BR BRPI0919738A patent/BRPI0919738A2/pt not_active IP Right Cessation
- 2009-09-25 EP EP09783402A patent/EP2334652A1/en not_active Withdrawn
- 2009-09-25 CN CN2009801376014A patent/CN102164924A/zh active Pending
- 2009-09-25 TW TW098132579A patent/TW201016696A/zh unknown
- 2009-09-25 MX MX2011002903A patent/MX2011002903A/es active IP Right Grant
- 2009-09-25 NZ NZ591845A patent/NZ591845A/xx not_active IP Right Cessation
- 2009-09-25 US US13/119,836 patent/US8703796B2/en not_active Expired - Fee Related
- 2009-09-25 AU AU2009295814A patent/AU2009295814A1/en not_active Abandoned
- 2009-09-25 JP JP2011528330A patent/JP5591807B2/ja not_active Expired - Fee Related
- 2009-09-25 BR BRPI0919292A patent/BRPI0919292A2/pt not_active IP Right Cessation
- 2009-09-25 TW TW098132575A patent/TW201016682A/zh unknown
- 2009-09-25 RU RU2011116128/04A patent/RU2011116128A/ru not_active Application Discontinuation
- 2009-09-25 AU AU2009295816A patent/AU2009295816A1/en not_active Abandoned
- 2009-09-25 US US13/119,835 patent/US9040565B2/en not_active Expired - Fee Related
- 2009-09-25 RU RU2011116131/04A patent/RU2011116131A/ru not_active Application Discontinuation
- 2009-09-25 CN CN2009801371627A patent/CN102164922A/zh active Pending
- 2009-09-25 CN CN2009801469428A patent/CN102224143A/zh active Pending
- 2009-09-25 KR KR1020117006846A patent/KR20110060910A/ko not_active Withdrawn
- 2009-09-25 JP JP2011528332A patent/JP5342646B2/ja not_active Expired - Fee Related
- 2009-09-25 US US13/119,832 patent/US8598190B2/en not_active Expired - Fee Related
- 2009-09-25 MX MX2011003094A patent/MX2011003094A/es not_active Application Discontinuation
- 2009-09-25 KR KR1020117006971A patent/KR20110056533A/ko not_active Withdrawn
- 2009-09-25 WO PCT/EP2009/062422 patent/WO2010034797A1/en not_active Ceased
- 2009-09-25 CA CA2737384A patent/CA2737384A1/en not_active Abandoned
- 2009-09-25 AR ARP090103704A patent/AR073685A1/es unknown
- 2009-09-25 CA CA2737839A patent/CA2737839A1/en not_active Abandoned
- 2009-09-25 WO PCT/EP2009/062424 patent/WO2010034798A1/en not_active Ceased
- 2009-09-25 AR ARP090103703A patent/AR073684A1/es unknown
- 2009-09-25 AR ARP090103706A patent/AR073403A1/es unknown
- 2009-09-25 JP JP2011528333A patent/JP5342647B2/ja not_active Expired - Fee Related
- 2009-09-25 JP JP2011528331A patent/JP5591808B2/ja not_active Expired - Fee Related
- 2009-09-25 WO PCT/EP2009/062425 patent/WO2010034799A1/en not_active Ceased
- 2009-09-25 WO PCT/EP2009/062421 patent/WO2010034796A1/en not_active Ceased
- 2009-09-25 MX MX2011003152A patent/MX2011003152A/es active IP Right Grant
- 2009-09-25 KR KR1020117006974A patent/KR20110065478A/ko not_active Withdrawn
- 2009-09-25 KR KR1020117006845A patent/KR20110056530A/ko not_active Withdrawn
- 2009-09-25 TW TW098132581A patent/TW201018684A/zh unknown
- 2009-09-25 US US13/119,834 patent/US8916599B2/en not_active Expired - Fee Related
2011
- 2011-02-09 ZA ZA2011/01041A patent/ZA201101041B/en unknown
- 2011-02-09 IL IL211137A patent/IL211137A0/en unknown
- 2011-02-09 IL IL211138A patent/IL211138A0/en unknown
- 2011-02-09 ZA ZA2011/01042A patent/ZA201101042B/en unknown
- 2011-02-10 IL IL211147A patent/IL211147A0/en unknown
- 2011-02-10 IL IL211148A patent/IL211148A0/en unknown

Also Published As

Publication number	Publication date
JP2012503630A (ja)	2012-02-09
US20120122930A1 (en)	2012-05-17
EP2350073A1 (en)	2011-08-03
CN102224143A (zh)	2011-10-19
KR20110060910A (ko)	2011-06-08
CA2738083A1 (en)	2010-04-01
IL211137A0 (en)	2011-04-28
CN102164924A (zh)	2011-08-24
MX2011003152A (es)	2011-04-27
JP2012503627A (ja)	2012-02-09
CA2737839A1 (en)	2010-04-01
TW201016696A (en)	2010-05-01
JP5591807B2 (ja)	2014-09-17
EP2334664A1 (en)	2011-06-22
TW201016682A (en)	2010-05-01
US8598190B2 (en)	2013-12-03
AR073684A1 (es)	2010-11-24
AU2009295815A1 (en)	2010-04-01
ZA201101041B (en)	2011-10-26
US20110275656A1 (en)	2011-11-10
US20110312935A1 (en)	2011-12-22
WO2010034798A1 (en)	2010-04-01
EP2334652A1 (en)	2011-06-22
MX2011002903A (es)	2011-04-11
NZ591845A (en)	2012-10-26
KR20110056530A (ko)	2011-05-30
JP5591808B2 (ja)	2014-09-17
UY32138A (es)	2010-04-30
AR073403A1 (es)	2010-11-03
JP2012503628A (ja)	2012-02-09
CA2737552A1 (en)	2010-04-01
US8916599B2 (en)	2014-12-23
RU2011116131A (ru)	2012-10-27
MX2011003094A (es)	2011-04-26
CN102164911A (zh)	2011-08-24
CA2737384A1 (en)	2010-04-01
AU2009295816A1 (en)	2010-04-01
CN102164922A (zh)	2011-08-24
RU2011116128A (ru)	2012-10-27
IL211138A0 (en)	2011-04-28
BRPI0919292A2 (pt)	2017-05-30
AU2009295813A1 (en)	2010-04-01
JP2012503629A (ja)	2012-02-09
US9040565B2 (en)	2015-05-26
US20120115902A1 (en)	2012-05-10
RU2011116129A (ru)	2012-10-27
IL211148A0 (en)	2011-04-28
EP2361252A1 (en)	2011-08-31
KR20110065478A (ko)	2011-06-15
MX2011002948A (es)	2011-04-26
AR073686A1 (es)	2010-11-24
JP5342646B2 (ja)	2013-11-13
WO2010034796A1 (en)	2010-04-01
WO2010034797A1 (en)	2010-04-01
IL211147A0 (en)	2011-04-28
EP2350073B1 (en)	2014-11-12
JP5342647B2 (ja)	2013-11-13
ZA201101042B (en)	2011-10-26
KR20110056533A (ko)	2011-05-30
TW201018669A (en)	2010-05-16
NZ591846A (en)	2012-11-30
AU2009295814A1 (en)	2010-04-01
NZ591843A (en)	2012-09-28
NZ591847A (en)	2013-01-25
AR073685A1 (es)	2010-11-24
RU2011116133A (ru)	2012-10-27
US8703796B2 (en)	2014-04-22
BRPI0919738A2 (pt)	2015-12-08
TW201018684A (en)	2010-05-16
WO2010034799A1 (en)	2010-04-01

Legal Events

Date	Code	Title	Description
2016-06-07	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE AS 5A E 6A ANUIDADES.
2016-09-27	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2370 DE 07-06-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

Publication	Publication Date	Title
BRPI1014956A2 (pt)	2018-07-24	agentes antinflamatórios.
NO2021006I1 (no)	2021-02-15	Quofenix, delafloksacin
BRPI1009315A2 (pt)	2016-03-08	agentes anti-inflamatórios
BRPI1010301A2 (pt)	2016-03-15	composição.
BRPI0913945A2 (pt)	2016-09-27	agentes anti-inflamatórios
BRPI0922845A2 (pt)	2015-12-29	pirazol-4-n-alcoxicarboxamidas como microbiocidas
BRPI0907376A2 (pt)	2015-07-14	Fotobiorretador
FIC20240018I1 (fi)	2024-06-04	Vamoroloni
BRPI0918430A2 (pt)	2015-11-24	4-fenil-1h-pirazóis inseticidas.
BRPI0908116A2 (pt)	2015-10-06	pulverizador
BRPI1008939A2 (pt)	2016-03-15	2-mercaptoquinolina-3-carboxamidas substituídas como moduladores de kncq2/3.
DK2259989T3 (da)	2013-02-04	Rem
UY33125A (es)	2011-07-29	Diaza-espiro-[5,5]-undecanos
EP2321062A4 (en)	2014-10-29	Sprayer
BRPI1011460A2 (pt)	2015-08-25	Composição desinfetante.
BRPI0917446A2 (pt)	2015-12-22	derivados de acilaminobenzamida.
BRPI0907522A2 (pt)	2019-09-24	biarlamidas
IT1396487B1 (it)	2012-12-14	Convogliatore.
BRPI0909634A2 (pt)	2015-09-22	2-aminoquinolinas
BRPI0907863A2 (pt)	2019-09-24	pirrolopirimidinacarboxamidas
AT507449A3 (de)	2010-11-15	Dämmstoffbefestiger
BRPI0916990A2 (pt)	2015-07-28	Combinações inseticidas
PT2277578T (pt)	2019-10-25	Nebulizador.
EP2309529A4 (en)	2015-06-03	PHOTO CATHODE
DK2254963T3 (da)	2012-09-17	Kerne-skal-flowforbedrer